Articles On Cardiex (ASX:CDX)

Apple’s new Watch alerts users to possible hypertension, but Cardiex’s CONNEQT Pulse delivers FDA-cleared data doctors need to diagnose and treat it The Pulse provides clinical-grade confirmation with structured cardiology reports and arte...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

UBS reckons healthcare will fare better than any other ASX sector Bell Potter says Monash IVF has fertile recovery prospects Telix wins FDA usage expansion for prostate cancer imaging     Financial giant UBS has declared that enough is e...

Medical device makers – including ASX-listed heart plays – are the likely winners from the US healthcare chaos Painchek hopes for US device approval by September Mayne Pharma flags legal action over Cosette bid but also waves an olive bra...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Highlights ASX 200 marked a new short-term high, driven by gains in gold and banking sectors Key miners including EPM and NC1 announced significant exploration updates Broader market sentiment remained positive across most s...

ASX adds 52 points, hitting a new 50-day high at 8,466.70 points Broad strength with 9 of 11 sectors on the up Gold and finance stocks outperform The ASX was on a roll today, climbing swiftly in the first hour of trade and maintaining mom...

Cardiex Ltd (ASX:CDX) has popped +11% intraday to 4.7cps as the smallcap healthcare stock wins a key approval from the TGA. That relates to its flagship ‘Conneqt Pulse’ device, which is ultimately a smartphone-compatible cardiovascular...

ASX climbs 0.3pc Gold stocks surge, up almost 2pc Retail sales soften, increasing chance of RBA rate cut The Australian share market worked hard for its gains today, seesawing between negative and positive territory before making a convin...

Cardiex is raising up to $6.5m via a $2.4m institutional placement and a $4.1m entitlement offer Funds will support the commercial expansion of CONNEQT Health, covering devices and digital arterial health solutions C2 Ventures has committe...

ASX falls as profit taking cuts banking stocks Energy sector booms on WDS project green light CPI comes in at 2.4pc vs expectations of 2.3pc   A trend of profit taking in the larger banking stocks has pushed the ASX lower by -0.13%, erasi...

Cardiex has formally lodged a TGA application to register its CONNEQT Pulse device in Australia, following FDA clearance in the US The move adds to a strong year that includes US shipments, a $3.25m capital raise, and inclusion on the US B...

The big-name biotechs present short-term trading opportunities for bold investors Nothing to see here, says Sigma Healthcare Broker reckons Mach 7 shares should be worth four times more than their current value   The topsy-turvy market ha...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Australia’s S&P/ASX 200 records its first back-to-back monthly fall since October 2023, down 3.39% in March Ten out 11 S&P/ASX 200 sectors posted losses with utilities the only sector in the black, up 1.52% Metal Powder Works rises...

Cardiex (ASX:CDX) shares have today remained flat on a happier Tuesday ahead of this month’s RBA decision as its CONNEQT cardiovascular health software integrates with the Apple Health application. Listen to the HotCopper podcast for in-...

Cardiex launches Cardiology Report in CONNEQT app to deliver clinical-grade heart insights to consumers New feature enhances at-home monitoring, translating advanced cardiovascular biomarkers into intuitive reports for patients and physici...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

 Opthea completes patient visits for the first of two phase III eye disease trials Syntara’s secondary burns scar program shows promise Biome is in the black   The first of Opthea’s (ASX:OPT) two phase III eye disease trials has hit a k...

Banks drag as Bendigo, Westpac slump Star Entertainment Group jumps on $650m refinancing Jack Ma’s return sparks tech rally in China   The ASX retreated by about 0.37% from Friday’s record high, with banks pulling the market down on Monda...

Global selloff hits markets after Trump’s tariffs Ethereum sinks and copper prices dive Fisher & Paykel crumbles over tariff costs   The global selloff is tearing through markets as traders headed for the exit following Trump’s tariff...

CardieX has commenced US deliveries of its CONNEQT Pulse The launch of the flagship device is also supported by the newly launched CONNEQT App The medtech secured a $3.25 million placement in December to accelerate product rollout and expa...

ASX falls as iron ore miners hit Fortescue reports bumper shipments Myer merger approved, while China gets a lift from officials   The ASX was down in the dumps on Thursday, with the benchmark S&P/ASX 200 falling by 0.7%.  The index w...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

Cardiex has announced a $3.25m placement to scale product rollouts and drive growth in its clinical trials business in 2025 FDA-cleared Pulse medical device has attracted 20,000+ waitlist members Pre-order sales already underway in the US...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX up, Xero leads gains Miners hit as iron ore drops, Variscan jumps 50pc Asian stocks down, Bitcoin hits US$93k before retreating   Aussie shares climbed higher on Thursday, powered by a rally in tech companies and the big banks. At the...

Stocks surge and US dollar jumps as Trump leads ASX rises  amid tight US election race Bitcoin hits record as Trump-linked trades soar   Stocks surged, Treasury yields soared, and the US dollar looked set for its biggest gain since March...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Cardiex opens US pre-orders for the CONNEQT Pulse, targeting consumer arterial health monitoring Over 20,000 sign-ups on the waitlist as Cardiex rolls out exclusive pre-order invitations Phased launch aims to streamline customer experience...

CardieX wins US$525,000 National Institutes of Health award for innovation in treatment of hypertensive disorders in pregnancy Medtech’s Pulse device is set to launch in November, expanding access to advanced arterial health monitoring The...

  ASX falls as tech sector drops on Euro chipmaker ASML’s report Gold prices near record highs with Evolution Mining rising Trump defends tariffs and Fed influence in recent interview   The ASX fell 0.41%, led by declines in the Tech sec...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Cardiex shares climb 15% on news the company is set to surpass its FY24 revenue projections Company is on track to double FY23 revenue amid a pipeline of new products and strategic partnerships The company has also announced its first glob...

ASX rose  as the RBA held interest rates at 12-year high 4.35pc All 11 sectors on the ASX gained, with significant moves from Pilbara and Fortescue  ASX to launch first bitcoin-linked ETF on Thursday   Aussie stocks bounced back by +0.8%...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

  Local markets are lucky to close a smidgen higher IT and Healthcare sectors offset a 2pc loss for Energy Small Caps led by Enova Mining   Australian sharemarkets lacked all the vim, vigour and vinegar one associates with victory on Mond...

Recce Pharma says Phase 1/2 study is achieving primary endpoints Cynata also reports also reports good progress in Phase 1 Cardiex is back on the ASX!   Recce to expand diabetes foot ulcer Phase 1/2 trial An independent Safety Committee h...

Stockhead’s Top 10 at 10, published each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percenta...

14 million raise for CardieX consisted of a placement, shareholder entitlement offer, and a funding commitment agreement. Placement was cornerstoned by Regal Funds Management. C2 Ventures, the investment vehicle of the company’s CEO and ch...